Surface-modified polycaprolactone nanoparticles for the brain-targeted delivery of nevirapine
Source abstract
Abstract
The low-density lipoprotein (LDL) receptors overexpressed in brain capillary endothelial cell (BCEC) membrane were successfully targeted by polysorbate 80 (PS80)-coated polycaprolactone (PCL) nanoparticles for brain delivery of nevirapine (NVP). The nanoparticles prepared by emulsion solvent evaporation technique were evaluated for mean particle size (nm), zeta potential (mV), percentage drug entrapment efficiency (% EE), percentage drug loading (% DL), Fourier transform infrared (FT-IR) spectroscopy, differential scanning calorimetry (DSC), scanning electron microscopy (SEM), transmission electron microscopy (TEM), in vitro drug release study, stability study and in vivo biodistribution study. The mean particle size (nm) of uncoated nanoparticles, NvPNPs5, and PS80-coated nanoparticles, P80NvPNPs5, were (128.43 ± 4.82) nm and (218.3 ± 7.3) nm, respectively. The SEM and TEM analysis showed small-sized (< 100 nm), spherical-shaped, smooth-surface nanoparticles with less aggregation. The zeta potential (mV) analysis showed stable nanoparticles with values (− 72.1 ± 0.00) mV, NvPNPs5; (− 16.2 ± 0.00) mV, P80NvPNPs5; (− 16.2 ± 0.00) mV, 6CFNvPNPs5; and (− 13.6 ± 0.00) mV, P806CFNvPNPs5. The FT-IR and DSC report indicated drug excipient compatibility. P80NvPNPs5 showed an in vitro drug release for 36 h and its release kinetic was best fitted in Higuchi model (R2 = 0.936). Korsemeyer Peppas model showed an anomalous non-Fickian drug release mechanism as n = 0.767. P80NvPNPs5 released NVP for 24 h in the brain with prolonged blood circulation for 48 h as compared with NvPNPs5 and free drug suspension, (p < 0.05) in in vivo biodistribution study in Swiss Wistar rat. The confocal laser scanning microscopy (CLSM) study showed uniform distribution of P80NvPNPs5 in rat BCECs for 24 h post i.v. administration. The present observation concludes the futuristic scope of P80NvPNPs5 nanoparticles for brain delivery of different antiretroviral drugs as well as other CNS active drugs to treat several CNS disorders.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Lipid Membrane Structure and Behavior · Nanoparticle-Based Drug Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (61)
Show source-provided references
1. Acharya SR, Reddy PRV (2016) Brain targeted delivery of paclitaxel using endogenous ligands. Asian J Pharm Sci 11:427–43810.1016/j.ajps.2015.11.121 ↗
2. Alyautdin RN, Petrov VE, Langer K, Berthold A, Kharkevich DA, Kreuter J (1997) Delivery of loperamide across the blood-brain barrier with polysorbate80 coated polybutylcyanoacrylate nanoparticles. Pharm Res 14:32532810.1023/A:1012098005098 ↗
3. Ambruosi A, Khalansky AS, Yamamoto H, Gelperina SE, Begley DJ, Kreuter J (2006) Biodistribution of Polysorbate 80 coated doxorubicin loaded [14C]-poly(butyl cyanoacrylate) nanoparticles after intravenous administration to Glioblastoma-bearing rats. J Drug Target 14:97–10510.1080/10611860600636135 ↗
4. Azimi B, Nourpanah P, Rabiee M, Arbab S (2014) Poly (ε-caprolactone) fiber: an overview. J Eng Fibers Fabrics 9:74–90
5. Badri W, Miladi K, Robin S, Viennet C, Nazari QA, Agusti G, Fessi H, Elaissari A (2017) Polycaprolactone based nanoparticles loaded with indomethacin for anti-inflammatory therapy: from preparation to ex vivo study. Pharm Res 34:1773–178310.1007/s11095-017-2166-7 ↗
6. Banker GS, Anderson NR (1990) Tablets. In: The theory and practice of Industrial pharmacy, 3rd (Edition) edn. Varghese Publishing House, Dadar, Bombay, India, pp 293–345
7. Bohn KA, Adkins CE, Mittapalli RK, Terell-Hall TB, Mohammad AS, Shah N et al (2016) Semi-automated rapid quantification of brain vessel density utilizing fluorescent microscopy. J Neurosci Methods 270:124–13110.1016/j.jneumeth.2016.06.012 ↗
8. Bondi ML, Craparo EF, Giammona G, Drago E (2010) Brain–targeted solid lipid nanoparticles containing Riluzole: preparation, characterization and biodistribution. Nanomed 5:25–3210.2217/nnm.09.67 ↗
9. Campos EVR, Oliveira JLD, Silva CMGD, Pascoli M, Pasquoto T, Lima R (2015) Polymeric and solid lipid nanoparticles for sustained release of Carbendazim and Tebuconazole in agricultural applications. Sci Rep 5:1380910.1038/srep13809 ↗
10. Chacko BJ, Palanisamy S, Gowrishankar NL, Honeypriya J, Sumathy A (2018) Effect of surfactant coating on brain targeting polymeric nanoparticles; a review. Indian J Pharm Sci 80:215–22210.4172/pharmaceutical-sciences.1000348 ↗
11. Chang J, Jallouli J, Kroubi M, Yuan XB, Feng W, Kang CH et al (2009) Characterisation of endocytosis of transferrin coated PLGA nanoparticles by the blood-brain barrier. Int J Pharm 379:285–29210.1016/j.ijpharm.2009.04.035 ↗
12. Chen Y, Liu L (2012) Modern methods for delivery of drugs across the blood-brain barrier. Adv Drug Deliv Rev 64:640–66510.1016/j.addr.2011.11.010 ↗
13. Choi SW, Kim WS, Kim JH (2003) Surface modification of functional nanoparticles for controlled drug delivery. J Dispers Sci Technol 24:475–48510.1081/DIS-120021803 ↗
14. Christoper GVP, Raghavan CV, Siddharth K, Kumar MSS, Prasad RH (2014) Formulation and optimization of coated PLGA–Zidovudine nanoparticles using factorial design and in vitro in vivo evaluations to determine brain targeting efficiency. Saudi Pharm J 22:133–14010.1016/j.jsps.2013.04.002 ↗
15. Daneman R, Prat A (2015) The blood-brain barrier. CHS Perspect Biol 7:020412
16. Dash S, Murthy PN, Nath LK, Choudhury P (2010) Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm Drug Res 67(3):217–223
17. Dora CP, Singh SK, Kumar S, Datusalia AK, Deep A (2010) Development and characterization of nanoparticles of Glibenclamide by solvent displacement method. Acta Pol Pharm Drug Res 67:283–290
18. Garcia EG, Andrieux K, Gil S, Couvreur P (2005) Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int J Pharm 298:274–29210.1016/j.ijpharm.2005.03.031 ↗
19. Ghaly ES, Sastre V (2014) Controlled release of ibuprofen nanoparticles: Physico-chemical characterization and drug release. Int J Pharm Pharm Sci 6:99–107
20. Goppert TM, Muller RH (2005) Polysorbate-stabilized solid lipid nanoparticles as colloidal carriers for intravenous targeting of drugs to the brain: Comparision of plasma protein adsorption pattern. J Drug Target 13:179–18710.1080/10611860500071292 ↗
21. Hague S, Md S, Sahni JK, Ali J, Baboota S (2014) Development and evaluation of brain-targeted intranasal alginate nanoparticles for treatment of depression. J Psychiatr Res 48:1–1210.1016/j.jpsychires.2013.10.011 ↗
22. Honary S, Zahir F (2013) Effect of zeta potential on the properties of Nano-drug delivery systems - a review (part 1). Trop J Pharm Res 12:255–264
23. Jia Y, Ji J, Wang F, Shi L, Yu J, Wang D (2016) Formulation, characterization and in-vitro/vivo study of Aclacinomycin a loaded solid lipid nanoparticles. Drug Deliv 23:1317–132510.3109/10717544.2014.974001 ↗
24. Jones AR, Shusta EV (2007) Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm Res 24:1759–177110.1007/s11095-007-9379-0 ↗
25. Kaur A, Jain S, Tiwary AK (2008) Mannan coated gelatin nanoparticles for sustained and targeted delivery of Didanosine: in-vitro and in-vivo evaluation. Acta Pharma 58:61–74
26. Kimulwo MJ, Okendo J, Ochieng W (2017) Plasma Nevirapine concentrations predict virological and adherence failure in Kenyan HIV-1 infected patients with extensive antiretroviral treatment exposure. PLoS One 12(2):1–1410.1371/journal.pone.0172960 ↗
27. Kreuter J (2001) Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47:65–8110.1016/S0169-409X(00)00122-8 ↗
28. Ku S, Yan F, Wang Y, Sun Y, Yang N, Ye L (2010) The blood-brain barrier penetration and distribution of PEGylated fluorescein-doped magnetic silica nanoparticles in rat brain. Biochem Biophys Res Commun 394:871–87610.1016/j.bbrc.2010.03.006 ↗
29. Kumar P, Mohan C, Uma Shankar MKS, Gulati M (2011) Physiochemical characterization and release rate studies of solid dispersions of ketoconazole with Pluronic F127 and PVP K-30. Ir J Pharm Res 10:685–694
30. Kuo YC, Lin PI, Wang CC (2011) Targeting Nevirapine delivery across human brain microvascular endothelial cells using transferrin–grafted poly (lactide-co-glycolide). Nanomedicine (London) 6(6):1011–102610.2217/nnm.11.25 ↗
31. Lahkar S, Das MK (2017) Effects of solvents on the development of biodegradable polymeric nanoparticles of Nevirapine. Int J ChemTech Res 10:735–747
32. Lahkar S, Das MK (2018) Surface modified kokum butter lipid nanoparticles for the brain targeted delivery of Nevirapine. J Microencapsul 35(7–8):680–69410.1080/02652048.2019.1573857 ↗
33. Lajoie JM, Shusta EV (2015) Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier. Annu Rev Pharmacol Toxicol 55:613–63110.1146/annurev-pharmtox-010814-124852 ↗
34. Lamorde M, Kibwika PB, Merry C (2011) Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin. J Antimicrob Chemother 66(1):180–18310.1093/jac/dkq411 ↗
35. Masserini M (2013) Nanoparticles for brain drug delivery. ISRN Biochem 2013:23842810.1155/2013/238428 ↗
36. Nevirapine (2007) Indian Pharmacoepia, vol 3, 5th edn. Indian Pharmacopoeia Commision, Ghaziabad, India, pp 819–820
37. Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R (2011) Nanoparticle: an overview of preparation and characterization. J Appl Pharm Sci 6:228–234
38. Pardridge WM (2005) The blood-brain barrier: bottleneck in brain drug development. NeuroRx 2:3–1410.1602/neurorx.2.1.3 ↗
39. Parikh T, Bommana MM, Squillante E (2010) Efficacy of surface charge in targeting pegylated nanoparticles of Sulpiride to the brain. Eur J Pharm Biopharm 74:442–45010.1016/j.ejpb.2009.11.001 ↗
40. Patil VC, Patil HC (2014) Neurological manifestations of HIV-AIDS at a tertiary care center in western Maharashtra. Int J Med Pub Health 4:210–21710.4103/2230-8598.137703 ↗
41. Petri B, Bootz A, Khalansky A, Hekmatara T, Muller R, Uhl R, Kreuter J, Gelperina S (2007) Chemotherapy of a braintumor using doxorubicin bound to surfactant-coated poly (butyl cyanoacrylate) nanoparticles: revisiting the role of surfactants. J Control Release 117:51–5810.1016/j.jconrel.2006.10.015 ↗
42. Phosphate buffer, pH 7.4 (1996) Indian Pharmacopoeia. Indian Pharmacopoeia Commision, Ghaziabad
43. Ramanujam R, Sundaram B, Janarthanan G, Devendran E, Venkadasalam M, John Milton MC (2018) Biodegradable Polycaprolactone nanoparticles based drug delivery systems: a short review. Biosci Biotech Res Asia 15:679–68510.13005/bbra/2676 ↗
44. Ravisankar P, Navya CN, Pravallika D, Sri DN (2015) A review on step-by-step analytical method validation. IOSR J Pharm 5(10):07–19
45. Reimold I, Domke D, Bender J, Seyfried CA, Radunz HE, Fricker G (2008) Delivery of nanoparticles to the brain detected by fluorescence microscopy. Eur J Pharm Biopharm 70:627–63210.1016/j.ejpb.2008.05.007 ↗
46. Sabin CA, Lundgren HD (2013) The natural history of HIV infection. Curr Opin HIV AIDS 8(4):311–317
47. Saksena NK, Smit TK (2005) HAART & the molecular biology of AIDS dementia complex. Indian J Med Res 121:256–269
48. Salmaso S, Caliceti P (2013) Stealth properties to improve therapeutic efficacy of drug nanocarriers. J Drug Deliv 2013:1–2010.1155/2013/374252 ↗
49. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood-brain barrier to treat neurodegenerative diseases. J Control Release 235:34–4710.1016/j.jconrel.2016.05.044 ↗
50. Sarmento B, Ferreira D, Veiga F, Ribeiro A (2006) Characterization of insulin-loaded alginate nanoparticles produced by Ionotropic pre-gelation through DSC and FTIR studies. Carbohydr Polym 66:1–710.1016/j.carbpol.2006.02.008 ↗
51. Souza SD (2014) A review of in vitro drug release test methods for nano-sized dosage forms. Adv Pharm 2014:1–12
52. Storm G, Belliot SO, Daemen T, Lasic DD (1995) Surface modification of nanoparticles to oppose uptake by the mononuclear phagocyte system. Adv Drug Deliv Rev 17:31–4810.1016/0169-409X(95)00039-A ↗
53. Sun W, Xie C, Wang H, Hu Y (2004) Specific role of Polysorbate 80 coating on the targeting of nanoparticles to the brain. Biomat 25:3065–307110.1016/j.biomaterials.2003.09.087 ↗
54. Tan IL, McArthur JC (2012) HIV-associated neurological disorders. CNS Drugs 26:123–13410.2165/11597770-000000000-00000 ↗
55. Tian XH, Lin XN, Wei F, Feng W, Huang ZC, Peng W et al (2011) Enhanced brain targeting of Temozolamide in Polysorbate 80 coated polybutylcyanoacrylate nanoparticles. Int J Nanomedicine 6:445–452
56. Usach I, Melis V, Peris JE (2013) Non-nucleoside reverse transcriptase inhibitors: a review on pharmacokinetics, pharmacodynamics, safety, and tolerability. J Int AIDS Soc 16:1–1410.7448/IAS.16.1.18567 ↗
57. Wang H, Jia Y, Hu JH, Zhang J, Zhang L (2013) Effect of preparation conditions on the size and encapsulation properties of mPEG-PLGA nanoparticles simultaneously loaded with vincristine sulfate and Curcumin. Pharm Dev Technol 18:694–70010.3109/10837450.2012.696267 ↗
58. Wilson B, Samanta MK, Santhi K, Kumar KPS, Paramakrishnan N, Suresh B (2008) Poly (n-butyl cyanoacrylate) nanoparticles coated with Polysorbate 80 for the targeted delivery of Rivastigmine to the brain to treat Alzheimer disease. Brain Res 1200:159–16810.1016/j.brainres.2008.01.039 ↗
59. Wong AD, Ye M, Levy AF, Rothstein JD, Bergles DE, Searson PC (2013) The blood-brain barrier: an engineering perspective. Front Neuroeng 6:1–2
60. Xiaojun T, Yu L, Qian H, Li Z, Zixuan H, Jiajin Y, Xiaoping Y, Jianzhuo H, Xing F (2018) Preparation and drug release study of novel nanopharmaceuticals with Polysorbate 80 surface adsorption. J Nanomater 2018: 1–1110.1155/2018/4718045 ↗
61. Yadav M, Parle M, Sharma N, Dhingra S, Raina N, Jindal DK (2017) Brain targeted oral delivery of doxycycline hydrochloride encapsulated tween 80 coated chitosan nanoparticles against ketamine-induced psychosis: behavioral, biochemical, neurochemical and histological alterations in mice. Drug Deliv 24:1429–144010.1080/10717544.2017.1377315 ↗